Review
doi: 10.1038/nrd1132.
Targeting JNK for therapeutic benefit: from junk to gold?
Affiliations
- PMID: 12815381
- DOI: 10.1038/nrd1132
Item in Clipboard
Review
Targeting JNK for therapeutic benefit: from junk to gold?
Nat Rev Drug Discov.
2003 Jul.
Abstract
The c-Jun NH(2)-terminal kinases (JNKs) phosphorylate and activate members of the activator protein-1 (AP-1) transcription factor family and other cellular factors implicated in regulating altered gene expression, cellular survival and proliferation in response to cytokines and growth factors, noxious stimuli and oncogenic transformation. Because these events are commonly associated with the pathogenesis of a number of human diseases, the potential of JNK inhibitors as therapeutics has attracted considerable interest. Here we discuss the evidence supporting the application of JNK inhibitors in inflammatory, vascular, neurodegenerative, metabolic and oncological diseases in humans, and describe the present status of drug discovery targeting JNK.
Similar articles
-
From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance.IUBMB Life. 2005 Apr-May;57(4-5):283-95. doi: 10.1080/15216540500097111. IUBMB Life. 2005. PMID: 16036612 Review.
-
Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.Cancer Res. 2004 Aug 1;64(15):5162-71. doi: 10.1158/0008-5472.CAN-04-0849. Cancer Res. 2004. PMID: 15289320
-
c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia.Glia. 2005 May;50(3):235-46. doi: 10.1002/glia.20173. Glia. 2005. PMID: 15739188
-
The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.Oncogene. 2003 Aug 28;22(36):5646-57. doi: 10.1038/sj.onc.1206673. Oncogene. 2003. PMID: 12944913
-
Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain.Neurosci Lett. 2004 May 6;361(1-3):64-7. doi: 10.1016/j.neulet.2004.02.041. Neurosci Lett. 2004. PMID: 15135894 Review.
Cited by
-
Non-cell-autonomous induction of tissue overgrowth by JNK/Ras cooperation in a Drosophila tumor model.Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13123-8. doi: 10.1073/pnas.0504170102. Epub 2005 Sep 6. Proc Natl Acad Sci U S A. 2005. PMID: 16150723 Free PMC article.
-
Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes.Proc Natl Acad Sci U S A. 2005 May 10;102(19):6931-5. doi: 10.1073/pnas.0502143102. Epub 2005 May 2. Proc Natl Acad Sci U S A. 2005. PMID: 15867147 Free PMC article.
-
Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo.Cell Signal. 2006 Jan;18(1):123-34. doi: 10.1016/j.cellsig.2005.04.001. Epub 2005 Jun 24. Cell Signal. 2006. PMID: 15979847 Free PMC article.
-
Pro-BDNF Contributes to Hypoxia/Reoxygenation Injury in Myocardial Microvascular Endothelial Cells: Roles of Receptors p75NTR and Sortilin and Activation of JNK and Caspase 3.Oxid Med Cell Longev. 2018 Jun 26;2018:3091424. doi: 10.1155/2018/3091424. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30046375 Free PMC article.
-
Ethyl pyruvate attenuates delayed experimental cerebral vasospasm following subarachnoid haemorrhage in rats: possible role of JNK pathway.RSC Adv. 2018 Feb 16;8(14):7726-7734. doi: 10.1039/c7ra10801j. eCollection 2018 Feb 14. RSC Adv. 2018. PMID: 35539121 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
